Metraipolis › archive › dc_720b1535635e
Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S-1 for neoadjuvant therapy of locally advanced gastric cancer with… — Europe PMC PMID:42087741
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42087741
- DOI
- 10.1002/ctm2.70679
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-02T20:35:28.203Z
- SHA-256 of the archived text
a2dd7e8407015df4f7e62777e35dbae3b3492084a5b6ead524dc53216e51cde3- Stable URL of this page
https://metraipolis.com/documento/dc_720b1535635e
How to cite
Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S-1 for neoadjuvant therapy of locally advanced gastric cancer with… — Europe PMC PMID:42087741 — Europe PMC (en), https://europepmc.org/article/MED/42087741 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_720b1535635e (Metraipolis archive dc_720b1535635e, sha256 a2dd7e8407015df4f7e62777e35dbae3b3492084a5b6ead524dc53216e51cde3)
BibTeX
@misc{dc720b1535635e,
title = {Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S-1 for neoadjuvant therapy of locally advanced gastric cancer with… — Europe PMC PMID:42087741},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42087741},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_720b1535635e; sha256 a2dd7e8407015df4f7e62777e35dbae3b3492084a5b6ead524dc53216e51cde3},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42087741. Agents can read the archived copy with the MCP tool read_document.